top of page
The Professional Network for Healthcare Experts
FDA expands Olumiant approval to adolescents with severe alopecia areata
The expanded indication extends Lilly's JAK inhibitor to adolescents aged 12 years and older with severe alopecia areata.
nuaxia
4 days ago1 min read
Lilly and InnoCare sign drug-discovery collaboration worth up to $3.35bn
Lilly and InnoCare have entered a multi-target research and licensing collaboration potentially worth $3.35 billion to discover and develop new medicines.
nuaxia
7 days ago2 min read
FDA approves Onswik as once-weekly basal insulin for adults with type 2 diabetes
The FDA has approved Lilly's Onswik as a once-weekly basal insulin for adults with type 2 diabetes, reducing the frequency of basal insulin injections from daily to weekly dosing.
nuaxia
7 days ago2 min read
FDA approves Inluriyo plus Verzenio for ESR1-mutated advanced breast cancer
The FDA has approved Inluriyo in combination with Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on endocrine therapy.
nuaxia
Sep 212 min read
Lilly and QurCan enter genetic-medicine collaboration worth up to $237m per programme
Lilly and QurCan Therapeutics have entered a multi-programme collaboration to develop nucleic-acid medicines for central and peripheral nervous system diseases using QurCan's TERP delivery platform.
nuaxia
Sep 162 min read
Lilly agrees acquisition of Merida Biosciences in deal worth up to $2.875bn
Lilly’s planned acquisition of Merida Biosciences adds an antibody-engineering platform designed to selectively remove disease-causing antibodies while preserving normal immune function.
nuaxia
Sep 12 min read
Eli Lilly Builds Infectious Disease Platform with Three-Acquisition Strategy
The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance.
nuaxia
May 303 min read
bottom of page